Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
04 déc. 2023 08h00 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
28 nov. 2023 08h00 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
22 nov. 2023 08h00 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
13 nov. 2023 08h00 HE | Sagimet Biosciences Inc.
On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024 Two abstracts, including late-breaker, accepted at the American...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
10 nov. 2023 08h30 HE | Sagimet Biosciences Inc.
Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
24 oct. 2023 11h00 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
18 oct. 2023 16h05 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
27 sept. 2023 16h05 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
21 août 2023 16h02 HE | Sagimet Biosciences Inc.
Completed upsized initial public offering raising $96.4 million in gross proceeds Presented positive data at EASL Congress 2023 from the planned interim readout of the Phase 2b FASCINATE-2 trial in...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
15 août 2023 16h04 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...